Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment

Late-Breaking Clinical Trial Shows Angiography-derived CathWorks FFRangio Improves Resource Utilization and Reduces Procedure Time

Mar. 29, 2026 at 2:29pm

Got story updates? Submit your updates here. ›

The ALL-RISE Trial, a landmark randomized controlled trial, demonstrated that CathWorks FFRangio, an angiography-derived physiology solution, met non-inferiority to invasive pressure wire guidance in terms of major adverse cardiac events at one year, while offering improved resource utilization and reduced procedure time benefits.

Why it matters

The positive results from the ALL-RISE Trial add to the growing body of clinical evidence supporting the use of CathWorks FFRangio, an innovative technology that can modernize the cath lab and provide enhanced information for decision-making in the diagnosis and treatment of coronary artery disease. This could lead to improved patient outcomes and more efficient cardiovascular care.

The details

The ALL-RISE Trial included 1930 patients enrolled across 59 global sites. Patients with coronary stenoses of intermediate significance were randomized to physiological assessment with CathWorks FFRangio or an invasive pressure wire-based approach. The primary endpoint was a composite of death, myocardial infarction or unplanned, clinically indicated revascularization at one year. The FFRangio group demonstrated improved resource utilization with reduced radiation exposure, less use of contrast medium, and shorter assessment and overall procedure times, despite a slightly higher rate of percutaneous coronary intervention.

  • The ALL-RISE Trial one-year results were presented at the American College of Cardiology's Annual Scientific Session (ACC.26) on March 29, 2026.
  • The ALL-RISE Trial one-year results were simultaneously published in the New England Journal of Medicine on March 29, 2026.

The players

Dr. Ajay J. Kirtane

From New York-Presbyterian/Columbia University Irving Medical Center, presented the one-year clinical outcomes of the ALL-RISE Trial on behalf of the trial investigators.

Dr. Martin B. Leon

The Executive Study Chair of the ALL-RISE Trial, from New York-Presbyterian/Columbia University Irving Medical Center.

Dr. William Fearon

The Study Chair and Global Principal Investigator of the ALL-RISE Trial, from Stanford University.

Dr. Allen Jeremias

The Co-Principal Investigator of the ALL-RISE Trial, from St. Francis Hospital & Heart Center.

Ramin Mousavi

The President & CEO of CathWorks, the company that developed the CathWorks FFRangio system.

Got photos? Submit your photos here. ›

What they’re saying

“Progress in cardiovascular disease is driven by strong partnership, relentless discovery and clinical rigor that challenges existing practices. The ALL-RISE Trial is a landmark, randomized controlled trial assessing how artificial intelligence and advanced computational science can obtain physiologic information once only obtained by an invasive procedure. The compelling results of the ALL-RISE Trial demonstrating CathWorks FFRangio had similar clinical outcomes to the current reference standard should serve as the impetus to increase adoption of physiology worldwide. With significant workflow advantages and a suite of intraprocedural tools that help optimize clinical decision making, CathWorks FFRangio can help advance cardiovascular care for clinicians and patients.”

— Dr. Martin B. Leon, Dr. Ajay J. Kirtane, Dr. William Fearon, and Dr. Allen Jeremias, Executive Study Chair, Study Chair and Global Principal Investigator, and Co-Principal Investigators of the ALL-RISE Trial

“We are grateful to the investigators, study coordinators and patients whose commitment to advancing science made the ALL-RISE Trial possible. The positive results from this landmark study add to an already robust body of clinical evidence generated from thousands of patients treated globally according to FFRangio guidance, reinforcing the distinct advantages that CathWorks FFRangio offers compared with invasive pressure wires and other ADP approaches. The ALL-RISE results mark a new dawn in coronary physiology and pave the way for CathWorks FFRangio to become the new standard of care for improving patient outcomes.”

— Ramin Mousavi, President & CEO of CathWorks

“Through our strategic partnership with CathWorks, we have seen the excitement and global adoption of CathWorks FFRangio as an innovative solution that modernizes the cath lab and delivers enhanced information for decision making. The ALL-RISE data affirm our confidence in FFRangio's transformative impact on the diagnosis and treatment of coronary artery disease. We are excited for the future with CathWorks and believe FFRangio is poised to become a new standard worldwide.”

— Jason Weidman, Senior Vice President and President of the Coronary & Renal Denervation business, Medtronic

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The positive results from the landmark ALL-RISE Trial demonstrate the potential for CathWorks FFRangio, an innovative angiography-derived physiology solution, to modernize the cath lab and improve cardiovascular care by providing enhanced information for clinical decision-making, while offering significant workflow advantages over invasive pressure wire-based approaches.